Dyax falls on 1Q13 revenue miss

Dyax Corp. (NASDAQ:DYAX) fell $1.44 (35%) to $2.69 on Friday after the company reported 1Q13 revenues that missed the Street and lowered its 2013 revenue guidance. The company reported 1Q revenues of $12 million, missing the Street's estimate of $16 million but up from $11.5 million in the prior year's quarter. Net sales of hereditary angioedema (HAE) drug Kalbitor ecallantide were $8.6 million, compared with $8 million in 1Q12. Dyax cut its full-year revenue guidance to $53-$58 million from $65-$70 million. The company now expects $40-$44 million in net Kalbitor sales, down from $52-$56 million previously. ...